NRC Health reports Q4 EPS $0.27, down from $0.38; FY revenue +7% but EPS $1.27 vs $1.46

NRC HEALTH

2022-FY EPS reported $1.27 revenue$151,568,000

Q4 diluted EPS $0.27 (vs $0.38 in Q4 2021); full-year 2022 diluted EPS $1.27 (vs $1.46).
FY 2022 revenue grew 7% year-over-year driven by core Human Understanding Program; Canadian ops phase-out partially offset.
$2.6M reclassification from substantial liquidation of Canadian subsidiary impacted other expense.
Capital allocation: $21.0M dividends, $27.6M share repurchases, $12.2M innovation/growth in 2022.
New client wins including St. Bernards Healthcare; received Best in KLAS 2023 Award for Patient Experience Improvement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NRC HEALTH reported financial results for fourth quarter and year ended December 31, 2022.

Period: fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 14, 2023, National Research Corporation, a Delaware corporation (the "Company"), issued a press release announcing its financial and operating results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

NRC HEALTH filing history →

Source: SEC EDGAR

accession 0001437749-23-003575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.